|By Marketwired .||
|April 30, 2014 01:12 PM EDT||
RALEIGH, NC--(Marketwired - April 30, 2014) - DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will release financial results for the first quarter ended March 31, 2014, after the close of the market on Monday, May 12, 2014.
The Company will host a conference call for investors on Tuesday, May 13, 2014, at 09:00 a.m. Eastern Time. To listen to the live call, individuals can access the webcast at the investor relations portion of the Company's website at http://ir.darabio.com/overview. Please log on to the website at least 15 minutes early to register, download and install any necessary audio software. For those who cannot listen to the live broadcast, replays will be available shortly after the call on the Dara BioSciences website.
About DARA BioSciences
DARA BioSciences Inc. of Raleigh, North Carolina, is an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments.
DARA holds exclusive U.S. marketing rights to Soltamox® (tamoxifen citrate) oral solution, the only liquid form of tamoxifen, used for the treatment and prevention of breast cancer. Soltamox offers a choice to patients who prefer or need a liquid form of tamoxifen. Tamoxifen is indicated for the treatment of ductal carcinoma in situ (DCIS); as adjuvant treatment of node-positive breast cancer; in the treatment of metastatic breast cancer; and for breast cancer risk reduction in high risk women. Currently, there are more than 1.8 million prescriptions of tamoxifen written on an annual basis in the United States. Between 30 and 70 percent of patients fail to complete their prescribed course of treatment, thereby diminishing its benefits in reducing the risk of breast cancer recurrence. Additional information is available at http://www.darabio.com.
May. 6, 2016 04:00 PM EDT Reads: 850
May. 6, 2016 04:00 PM EDT Reads: 1,206
May. 6, 2016 03:15 PM EDT Reads: 229
May. 6, 2016 03:00 PM EDT Reads: 253
May. 6, 2016 02:42 PM EDT Reads: 250
May. 6, 2016 02:15 PM EDT Reads: 911
May. 6, 2016 02:02 PM EDT Reads: 250
May. 6, 2016 01:45 PM EDT Reads: 1,373
May. 6, 2016 01:00 PM EDT Reads: 1,411
May. 6, 2016 12:45 PM EDT Reads: 1,186
May. 6, 2016 12:30 PM EDT Reads: 1,217
May. 6, 2016 12:00 PM EDT Reads: 842
May. 6, 2016 11:57 AM EDT Reads: 273
May. 6, 2016 10:30 AM EDT Reads: 1,597
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
May. 6, 2016 10:00 AM EDT Reads: 1,532